PAREXEL Launches Next Generation Data-Driven Monitoring Capabilities Within Perceptive MyTrials® Solution

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched next generation risk-based monitoring capabilities, expanding its Perceptive MyTrials® Data-Driven Monitoring (DDM) solution. Data-Driven Monitoring now further enables clients to perform cross-study analysis of quality, risk, and monitoring work effort by combining analytics, reporting and monitoring activity into a single cohesive solution. The enhancements increase a drug developer's ability to demonstrate appropriate oversight and control of site-related risk, quality, and performance while simplifying monitoring governance and execution."Centralized monitoring methods are being encouraged by the U.S. Food and Drug Administration (FDA) and other regulatory bodies. By combining our DDM and monitoring solution, PAREXEL clients now have the ability to bridge real-time information gaps between centralized analysts and in-the-field monitoring teams, reducing risk, ensuring documentation, and increasing quality," said Drew Garty, Senior Director, Product Management, PAREXEL.The Perceptive MyTrials Data-Driven Monitoring solution uses a unique, algorithmic-based approach to clinical monitoring to determine risk and monitor workload, enabling flexible and scalable decision-making. Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials platform, an integrated suite of applications for managing clinical trials."Our enhanced data-driven monitoring solution provides users with greater control over site risk and resourcing, building on PAREXEL's long-standing track record of developing innovative technologies to continuously improve clinical processes," said Xavier Flinois, President of PAREXEL Informatics. "These updates are the latest example of our continued commitment to make the drug development process more efficient for our clients."